Evidence map›Paper›PMID 37182801›Full record

Trial reportAnnals of oncology : official journal of the European Society for Medical Oncology2023

A multicenter, open-label, randomized, phase II study of cediranib with or without lenalidomide in iodine 131-refractory differentiated thyroid cancer.

A J Rosenberg, C-Y Liao, T Karrison, J A de Souza, F P Worden, B Libao, M K Krzyzanowska, D N Hayes, E Winquist, V Saloura and 7 more

Open access · bronzeAbstract readRandomized Controlled TrialMulticenter StudyClinical Trial, Phase II
PubMed Full text at PMC Publisher
In one paragraph

Trial report in Annals of oncology : official journal of the European Society for Medical Oncology, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
0.8field-weighted citation impact, top 25% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed, 4 citations in OpenAlex.

  1. Review
  2. Review
  3. Article
  4. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

17 authors at 12 institutions in 2 countries.

A J RosenbergDepartment of Medicine, University of Chicago, Chicago, USA; University of Chicago Comprehensive Cancer Center, Chicago, USA. Electronic address: Arirosenberg@medicine.bsd.uchicago.edu.
C-Y LiaoDepartment of Medicine, University of Chicago, Chicago, USA; University of Chicago Comprehensive Cancer Center, Chicago, USA.
T KarrisonDepartment of Public Health Sciences, University of Chicago, Chicago, USA.
J A de SouzaHCA Healthcare, Nashville, USA.
F P WordenUniversity of Michigan Comprehensive Cancer Center, Ann Arbor, USA.
B LibaoDepartment of Medicine, University of Chicago, Chicago, USA.
M K KrzyzanowskaPrincess Margaret Cancer Centre, Toronto, Canada.
D N HayesLineberger Comprehensive Cancer Center, The University of North Carolina at Chapel Hill, Chapel Hill, USA.
E WinquistDepartment of Oncology, University of Western Ontario and London Health Sciences Centre, London, Canada.
V SalouraNational Cancer Institute, Bethesda, USA.
K PrescottUniversity of Illinois Chicago, Chicago, USA.
V M VillaflorCity of Hope Comprehensive Cancer Center, Duarte, USA.
T Y SeiwertDepartment of Oncology, Sidney Kimmel Comprehensive Cancer Center, Johns Hopkins University, Baltimore, USA.
R B SchechterDepartment of Medicine, University of Chicago, Chicago, USA.
W M StadlerDepartment of Medicine, University of Chicago, Chicago, USA; University of Chicago Comprehensive Cancer Center, Chicago, USA.
E E W CohenMoores Cancer Center at UC San Diego, La Jolla, USA.
E E VokesDepartment of Medicine, University of Chicago, Chicago, USA; University of Chicago Comprehensive Cancer Center, Chicago, USA.
University of Chicago · USChicago Department of Public Health · USCity of Hope · USHCA Healthcare · USJohns Hopkins University · USNational Cancer Institute · USPrincess Margaret Cancer Centre · CAUniversity of California San Diego · USUniversity of Illinois Chicago · USUniversity of Michigan · USUniversity of North Carolina at Chapel Hill · USWestern University · CA

Funding

Phase I Molecular and Clinical Pharmacodynamic Trials ETCTNUM1CA186717 · NCI · BECKMAN RESEARCH INSTITUTE/CITY OF HOPE · PI A. Dimitrios Colevas, Alexey V. Danilov · 2014 to 2026
$19.8M
Experimental Therapeutics: Clinical Trials Network with Phase I EmphasisUM1CA186705 · NCI · UNIVERSITY OF CHICAGO · PI MAITLAND, MICHAEL L., RATAIN, MARK J · 2014 to 2015
$987k
NCI NIH HHS UM1 CA186705NCI NIH HHS UM1 CA186717
6 · The paper itself

Abstract

backgroundMultitargeted tyrosine kinase inhibitors (TKIs) of the vascular endothelial growth factor receptor (VEGFR) pathway have activity in differentiated thyroid cancer (DTC). Lenalidomide demonstrated preliminary efficacy in DTC, but its safety and efficacy in combination with VEGFR-targeted TKIs is unknown. We sought to determine the safety and efficacy of cediranib, a VEGFR-targeted TKI, with or without lenalidomide, in the treatment of iodine 131-refractory DTC. PATIENTS AND

methodsIn this multicenter, open-label, randomized, phase II clinical trial, 110 patients were enrolled and randomized to cediranib alone or cediranib with lenalidomide. The primary endpoint was progression-free survival (PFS). Secondary endpoints included response rate, duration of response, toxicity, and overall survival (OS). Patients (≥18 years of age) with DTC who were refractory to further surgical or radioactive iodine (RAI) therapy as reviewed at a multispecialty tumor board conference, and evidence of disease progression within the previous 12 months and no more than one prior line of systemic therapy were eligible.

resultsOf the 110 patients, 108 started therapy and were assessable for efficacy. The median PFS was 14.8 months [95% confidence interval (CI) 8.5-23.8 months] in the cediranib arm and 11.3 months (95% CI 8.7-18.9 months) in the cediranib with lenalidomide arm (P = 0.36). The 2-year OS was 64.8% (95% CI 43.3% to 86.4%) and 75.3% (95% CI 59.4% to 91.0%), respectively (P = 0.80). The serious adverse event rate was 41% in the cediranib arm and 46% in the cediranib with lenalidomide arm.

conclusionsSingle-agent therapy with cediranib showed promising efficacy in RAI-refractory DTC similar to other VEGFR-targeted TKIs, while the addition of lenalidomide did not result in clinically meaningful improvements in outcomes.

Indexed as

AdenocarcinomaThyroid NeoplasmsHumansIndolesInfantIodine RadioisotopesLenalidomideQuinazolinesReceptors, Vascular Endothelial Growth FactorVascular Endothelial Growth Factor AcediranibIndolesIodine-131Iodine RadioisotopesLenalidomideQuinazolinesReceptors, Vascular Endothelial Growth FactorVascular Endothelial Growth Factor Aantiangiogeniccediranibimmunomodulationlenalidomidethyroid cancertyrosine kinase inhibitor

Identifiers

PMID37182801
PMCPMC10696593
OpenAlexW4376272391

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.